A long-term follow-up study on hepatitis B surface antigen–positive patients undergoing allogeneic hematopoietic stem cell transplantation

The long-term hepatic complications after allogeneic hematopoietic stem cell transplantation (HSCT) in hepatitis B virus (HBV) endemic area are unknown. We examined the serological and liver-related outcome of 803 consecutive patients who received allogeneic HSCTs, with a median follow-up period of...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2005-07, Vol.106 (2), p.464-469
Main Authors: Hui, Chee-kin, Lie, Albert, Au, Wing-yan, Leung, Yu-hung, Ma, Shing-yan, Cheung, Winnie W.W., Zhang, Hai-ying, Chim, Chor-sum, Kwong, Yok-lam, Liang, Raymond, Lau, George K.K.
Format: Article
Language:English
Subjects:
Adolescent
Adoptive Transfer
Adult
Aged
Biological and medical sciences
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation - adverse effects
Hepatitis B Antibodies - blood
Hepatitis B Surface Antigens - metabolism
Hepatitis B, Chronic - etiology
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - transmission
Human viral diseases
Humans
Infectious diseases
Longitudinal Studies
Male
Medical sciences
Middle Aged
Transplantation, Homologous
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The long-term hepatic complications after allogeneic hematopoietic stem cell transplantation (HSCT) in hepatitis B virus (HBV) endemic area are unknown. We examined the serological and liver-related outcome of 803 consecutive patients who received allogeneic HSCTs, with a median follow-up period of 83 months (range, 0.5-155 months). Late HBV-related hepatitis occurred in 2 of the 721 hepatitis B surface antigen–negative (HBsAg–) recipients compared with 16 of the 82 HBsAg+ recipients after HSCT (0.3% vs 19.5%; P < .001 by log-rank). Liver cirrhosis developed in 8 of the 82 HBsAg+ recipients compared with none of the 721 HBsAg– recipients (9.8% vs 0%; P < .001 by log-rank). Twenty of the 31 (64.5%) HBsAg+ recipients of hematopoietic stem cells from donors with natural immunity to HBV had sustained serologic clearance of HBsAg after HSCT. Eight of the 62 recipients without sustained HBsAg clearance compared with none of the 20 recipients with sustained HBsAg clearance developed liver cirrhosis (12.9% vs 0%; P = .02 by log-rank). Our study showed that long-term hepatic complications occur in a significant proportion of HBsAg+ patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained serologic clearance of HBsAg after HSCT.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2005-02-0698